Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Lanqi Ren
Institution:
Zhejiang Chinese Medical University
Observed institution:
Zhejiang Chinese Medical University
ORCID:
0009-0001-9245-1321
Observed ORCID:
0009-0001-9245-1321
OpenAlex ID:
A5108308059
RNA m6A methylation regulators in liver cancer
2024
·
Qiaoping Xu
, Ning Ren
, et al.
·
Cancer Cell International
·
26
PDF
Ferroptosis: a new promising target for hepatocellular carcinoma therapy
2023
·
Qiaoping Xu
, Lanqi Ren
, et al.
·
Molecular and Cellular Biochemistry
·
15
Functions and mechanisms of RNA m6A regulators in breast cancer (Review)
2024
·
Yibei Yang
, Feng Gao
, et al.
·
International Journal of Oncology
·
7
PDF
Relacorilant plus nab-paclitaxel for recurrent, platinum-resistant ovarian cancer: a cost-effectiveness study
2025
·
Yidong Zhou
, Fei Tong
, et al.
·
Journal of Gynecologic Oncology
·
6
PDF
Role of N6‑methyladenosine in the pathogenesis, diagnosis and treatment of prostate cancer (Review)
2024
·
Junjie Pan
, Fei Tong
, et al.
·
Oncology Reports
·
6
PDF
83P Cost-effectiveness analysis of talazoparib maintenance treatment for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US
2024
·
Qiaoping Xu
, Junjie Pan
, et al.
·
Scientific Reports
·
6
Economic evaluation of third-line neratinib plus capecitabine versus lapatinib plus capecitabine with HER2+ metastatic breast cancer
2023
·
Lanqi Ren
, Ning Ren
, et al.
·
Frontiers in Oncology
·
3
PDF
Anti-inflammatory effects of 1,8-cineol via NF-κB/COX-2 pathway in BEAS-2B cells and alleviates bronchoconstriction and airway hyperreactivity in ovalbumin sensitized mice
2026
·
Yanhong Wang
, Qianqian Jiang
, et al.
·
Frontiers in Immunology
·
1
PDF
Relacorilant Plus Nab-Paclitaxel For Recurrent,Platinum-Resistant Ovarian Cancer: A Cost-Effectiveness Study
2025
·
Qiaoping Xu
, Yidong Zhou
, et al.
·
International Journal of Gynecological Cancer
Cost-effectiveness of Trastuzumab emtansine and Capecitabine plus lapatinib in adjuvant treatment of Human Epidermal Growth Factor Receptor 2– Positive Metastatic Breast Cancer in China
2024
·
Yibei Yang
, Lanqi Ren
, et al.
·
Research Square
PDF
Cost-effectiveness of Metronomic chemotherapy vs Weekly Intravenous Paclitaxel in patients with ER+/HER2-Metastatic Breast Cancer
2024
·
Ning Ren
, Qiaoping Xu
, et al.
·
Research Square
PDF
Show more works
View as search
Works count:
11
Citation count:
70
H-index:
6
I10-index:
2
Year
Topic
Type